+ Filter
Loading...
Custom Services order now ship next day

Anti-CD79B Recombinant Antibody Products

Anti-CD79B Recombinant Antibody Products

    • Target: cyCD79b
    • Linker: MCC(Maleimidomethyl cyclohexane-1-carboxylate))
    • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
    Go to compare Compare
    • Target: CD79b
    • Linker: SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
    • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
    Go to compare Compare
    • Target: CD79b
    • Linker: SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
    • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
    Go to compare Compare
    • Target: CD79b
    • Linker: VC(Valine-citrulline)
    • Drug: MMAE (monomethyl auristatin E)
    Go to compare Compare
    • Target: CD79b
    • Linker: mcc (Maleimidomethyl cyclohexane-1-carboxylate)
    • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
    Go to compare Compare
    • Target: CD79b
    • Linker: MCC(Maleimidomethyl cyclohexane-1-carboxylate)
    • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
    Go to compare Compare
    • Target: CD79b
    • Linker: SPP(N-succinimidyl-4-(2-pyridyldithio)pentanoate)
    • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
    Go to compare Compare
    • Target: CD79b
    • Linker: mc(maleimidocaproyl)
    • Drug: MMAF(monomethyl auristatin F)
    Go to compare Compare
    • Target: CD79b
    • Linker: MCC (4-(Nmaleimidomethyl)cyclohexane-1 carboxylate)
    • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
    Go to compare Compare
More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs supplies excellent and innovative recombinant antibodies specifically targeting CD79B, tailored for biomedical research. We are dedicated to facilitating research and discovery by offering recombinant products that meet the highest standards of quality and performance. Our commitment extends beyond providing exceptional value; we also deliver superb technical support to assist researchers in maximizing their results. By choosing our CD79B antibodies, you gain reliable tools that enhance your investigations and contribute to meaningful advancements in biomedical science.

CD79B: A Crucial target in B-cell Malignancies

CD79B is a protein that is part of the B-cell antigen receptor complex. It plays a crucial role in B-cell activation and signaling. In research, understanding CD79B is important as it provides insights into the normal functioning of B cells and immune responses. Dysregulation of CD79B has been implicated in various diseases, particularly B-cell malignancies. Studying CD79B can help in the development of targeted therapies for these disorders. It can also aid in the design of diagnostic tools to detect and monitor B-cell related diseases. Additionally, exploring CD79B may contribute to a better understanding of the immune system and its interactions with other cells and molecules.

Alternative Names

CD79b molecule; B29; IGB; AGM6; Igbeta

Background

CD79B (CD79b Molecule) is a Protein Coding gene. Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia, Non-Bruton Type. Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Innate Immune System. Gene Ontology (GO) annotations related to this gene include transmembrane signaling receptor activity.

Anti-CD79B rAb Products

We provided high-quality anti-CD79B recombinant antibody products to accelerate biological research and discovery of CD79B target.

Cat. No. Product Name Target Species Host Species Applications
TAB-897 Humanized Anti-CD79B Recombinant Antibody (clone Polatuzumab) Human Human Neut; ELISA; IF; IP; FuncS; FC; ICC
FAMAB-0058YC Hamster Anti-Cd79b Recombinant Antibody (clone HM79-16) Mouse Hamster FuncS
HPAB-0364LY Human Anti-CD79B Recombinant Antibody Human Human Inhib; ELISA
HPAB-618-FY Human Anti-CD79B Recombinant Antibody Human Human FC; ELISA
HPAB-1491-FY Human Anti-CD79B Recombinant Antibody (clone P2C2) Human Human ELISA; WB

Creative Quality Control

To fulfill customer requirements, we have put in place a strict quality management system to guarantee the quality of our products and offer customers high-quality technical services.

Fig.1 SDS-PAGE analysis of FAMAB-0058YC. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-CD79B antibody
(Cat# FAMAB-0058YC, Creative Biolabs).

Fig.2 SEC-HPLC analysis of FAMAB-0058YC. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-CD79B antibody
(Cat# FAMAB-0058YC, Creative Biolabs).

Fig.3 ELISA analysis of TAB-897. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-CD79B antibody
(Cat# TAB-897, Creative Biolabs).

Fig.4 WB analysis of TAB-897. (Creative Biolabs Original)Fig.4 WB analysis of anti-CD79B antibody
(Cat# TAB-897, Creative Biolabs).

Customer Reviews

Excellent
E**yn
Humanized Anti-CD79B Recombinant Antibody (clone Polatuzumab) (Cat#: TAB-897)
This anti-CD79B recombinant human antibody was used to test the expression of protein CD79B in cells. I employed IP and ICC techniques for detection. The results were promising. With IP, it effectively captured the target protein, providing valuable insights into protein-protein interactions. ICC allowed for precise localization of CD79B within cells, aiding in the understanding of its cellular distribution.
9/Oct/2021
Excellent
C**rk
Hamster Anti-Cd79b Recombinant Antibody (clone HM79-16) (Cat#: FAMAB-0058YC)
This antibody was employed to detect the expression and localization of Cd79b in tumor cells. The antibody showed excellent specificity and sensitivity, accurately detecting the presence of Cd79b in the samples. This allowed for precise quantification and analysis of Cd79b levels, which was crucial for my study. The antibody provided reliable and reproducible results and contributed significantly to my understanding of the role of Cd79b in B-cell malignancies.
18/Jul/2022

rAb Production

We possess several years of experience in the production and optimization of recombinant antibodies. By offering the finest quality service, we supply you with recombinant antibody products of high quality and standard in the shortest possible time.

Featured Anti-CD79B Recombinant Antibody Production PlatformsFig.5 Anti-CD79B recombinant antibody production: milligram-scale. (Creative Biolabs Original)
Fig.5 Milligram-scale recombinant antibody production.

Fig.6 Anti-CD79B recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.6 Gram-scale recombinant antibody production

rAb Modalities

Creative Biolabs possesses a variety of high-quality antibody formats to fulfill the diverse demands of customers. The range of antibody formats includes, but is not limited to, full-length, VH, Fab, and scFv, among others.

Fig.7 Diverse anti-CD79B recombinant antibody production and modalities. (Creative Biolabs Original)Fig.7 Full Length Anti-CD79B Recombinant Antibody Production and Modalities

Drug Information Targeting CD79B

Table 1. Therapeutic approaches targeting CD79B in clinical development.

Research phase Company Classification Indications Details
Launched - 2019 Chugai Pharmaceutical Drug Conjugates Chronic lymphocytic leukemia This is a CD79b-targeted antibody-drug conjugate comprising an anti-CD79b monoclonal antibody and a monomethyl auristatin E (MMAE)-based payload.
Phase II Hangzhou Huadong Medicine Group Biologics Autoimmune disease It is a bispecific humanized diabody targeting both CD32B and CD79B, is in phase II development at Provention Bio (now Sanofi) for the treatment of systemic lupus erythematosus.
Phase I Janssen Biologics Chronic lymphocytic leukemia This is a T-cell redirecting tri-specific antibody developed by Janssen, is in early clinical development in an injectable subcutaneous formulation for the treatment of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Phase I Genentech Drug Conjugates Non-Hodgkin lymphoma It is an antibody-drug conjugate that has been in phase I clinical trials for the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma; however no recent developments have been reported.

For more details regarding our anti-CD79B recombinant antibody products, please do not hesitate to contact us. Our knowledgeable team is here to provide assistance and address any inquiries you may have. We look forward to establishing a mutually advantageous partnership that supports your research goals.

  • 0
  • 0
Cart
    Go to compare

    Go to compare